Misonix, Inc. (MSON)
| Market Cap | 401.75M |
| Revenue (ttm) | 68.05M |
| Net Income (ttm) | -18.54M |
| Shares Out | 17.41M |
| EPS (ttm) | -1.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 24 |
| Last Price | $23.02 |
| Previous Close | $23.11 |
| Change ($) | -0.09 |
| Change (%) | -0.39% |
| Day's Open | 23.22 |
| Day's Range | 22.81 - 23.22 |
| Day's Volume | 27,243 |
| 52-Week Range | 10.57 - 24.42 |
Leading Medical Tech Executive Brings Extensive Industry Knowledge, Strategic Leadership and Financial Expertise to Board Leading Medical Tech Executive Brings Extensive Industry Knowledge, Strategic Le...
FARMINGDALE, N.Y., May 10, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical ...
Misonix Raises Guidance for neXus® Ultrasonic Surgical System to 200 Unit Placements by Fiscal 2021 Year-End Misonix Raises Guidance for neXus® Ultrasonic Surgical System to 200 Unit Placements by Fisca...
FARMINGDALE, N.Y., April 20, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinica...
SonicOne® Ultrasonic Wound Debridement Franchise to Provide Comprehensive Procedural Solution for Charcot Foot by Adding Complementary External Fixation Product to Reconstructive Tissue Offering SonicOn...
FARMINGDALE, N.Y., March 04, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative ...
FARMINGDALE, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinica...
FARMINGDALE, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical...
FARMINGDALE, N.Y., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative p...
FARMINGDALE, N.Y., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical...
FARMINGDALE, N.Y., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical...
FARMINGDALE, N.Y., Dec. 18, 2020 (GLOBE NEWSWIRE) -- 2020) – Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance ...
FARMINGDALE, N.Y., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical...
FARMINGDALE, N.Y., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical...
Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q1 2021 Results - Earnings Call Transcript
FARMINGDALE, N.Y., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative p...
FARMINGDALE, N.Y., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical...
Confirms Improving Revenue Trends, Rise in Procedure Volumes and Strong New Product Adoption Confirms Improving Revenue Trends, Rise in Procedure Volumes and Strong New Product Adoption
Expands Misonix’s Wound Tissue Regeneration Franchise and Complements Nexus SonicOne® Strategy Expands Misonix’s Wound Tissue Regeneration Franchise and Complements Nexus SonicOne® Strategy
FARMINGDALE, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance cli...
Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q4 2020 Results - Earnings Call Transcript
Shares of Misonix (NASDAQ:MSON) were flat in after-market trading after the company reported Q4 results.
FARMINGDALE, N.Y., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerativ...
FARMINGDALE, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clin...
FARMINGDALE, N.Y., July 30, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clin...
Full Year Revenue of Approximately $62.3 Million
Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q3 2020 Results - Earnings Call Transcript
With Focus on Maintaining Our Objective of Shareholder Value Creation, Company to Prioritize Cash Preservation Through Expense Reduction, Workforce Efficiency and Operational Synergies
No matter which strategy is employed or what types of stocks are sought after, investors want to see returns. The post 7 ‘Strong Buy’ Stocks With Over 50% Upside Potential appeared first on InvestorPl...
Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q2 2020 Results - Earnings Call Transcript
FARMINGDALE, N.Y., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerati...
FARMINGDALE, N.Y., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative...
Reiterates Expectation for Fiscal 2020 Full Year Pro Forma Revenue Growth of 20% Reiterates Expectation for Fiscal 2020 Full Year Pro Forma Revenue Growth of 20%
FARMINGDALE, N.Y., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerati...
Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q1 2020 Results - Earnings Call Transcript
FARMINGDALE, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance cl...
Misonix Inc (NASDAQ:MSON) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019.
Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q4 2019 Results - Earnings Call Transcript
Misonix (NASDAQ: MSON) releases its next round of earnings this Wednesday, August 14.
Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q3 2019 Results - Earnings Call Transcript
Misonix' (MSON) CEO Stavros Vizirgianakis on Acquisition of Solsys Medical - Transcript
Medical device maker Misonix, Inc. announced Thursday that it entered a definitive agreement to acquire privately held Solsys Medical, LLC in an all-stock transaction valued at about $97 million.
About MSON
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic ... [Read more...]
| Industry Medical Devices | IPO Date Jan 23, 1992 |
| Stock Exchange NASDAQ | Ticker Symbol MSON |
Financial Performance
In 2020, Misonix's revenue was $62.48 million, an increase of 60.84% compared to the previous year's $38.85 million. Losses were -$17.42 million, 135.8% more than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for Misonix stock is "Strong Buy." The 12-month stock price forecast is 23.00, which is a decrease of -0.09% from the latest price.